Apolipoprotein A-I (apoA-I) mimetic peptides bind bioactive lipids and endotoxin (LPS) with higher affinity than apoA-I and may be novel therapeutic agents for treatment of inflammatory diseases including cardiovascular and inflammatory bowel disease and cancer [10–14]. This evidence concerns the gene APOA1 and inflammatory bowel disease.